

AN ORDINANCE 100423

AUTHORIZING THE ACCEPTANCE OF A CLINICAL STUDY AGREEMENT IN THE AMOUNT OF \$53,175.00 FROM MERCK & COMPANY, INC. FOR THE SAN ANTONIO METROPOLITAN HEALTH DISTRICT TO PARTICIPATE IN A STUDY TO EVALUATE A VACCINE AGAINST MEASLES, MUMPS AND RUBELLA DISEASES IN HEALTHY CHILDREN 12 TO 18 MONTHS OF AGE BEGINNING ON JANUARY 10, 2005 AND CONTINUING FOR APPROXIMATELY TEN (10) MONTHS; AUTHORIZING THE EXECUTION OF A CLINICAL STUDY AGREEMENT WITH MERCK & COMPANY, INC.; ESTABLISHING A FUND; ADOPTING A BUDGET; APPROVING THE PERSONNEL COMPLEMENT; AND AUTHORIZING PAYMENTS FOR CONTRACTUAL SERVICES.

* * * * *

WHEREAS, the San Antonio Metropolitan Health District (SAMHD) operates a program that provides immunizations to children for the prevention of diseases such as measles, rubella, mumps, diphtheria, tetanus, polio, haemophilus influenza b, pertussis, hepatitis A and B, and varicella; and

WHEREAS, Merck and Company, Inc., a manufacturer of medications and vaccines, has offered an agreement to the SAMHD to participate in a clinical study in order to evaluate a vaccine against measles, mumps and rubella diseases in healthy children 12 to 18 months of age; and

WHEREAS, the SAMHD wishes to participate in this effort and for participation in said clinical trial study, will receive up to \$53,175.00 beginning on January 10, 2005 and continuing approximately ten months; and

WHEREAS, it is now necessary to authorize the acceptance and execution of said agreement, establish a fund, adopt a budget, approve a personnel complement, and authorize the payment of stipends of up to \$50.00 to the family of each participant in the study; **NOW THEREFORE:**

BE IT ORDAINED BY THE CITY COUNCIL OF THE CITY OF SAN ANTONIO:

SECTION 1. The Interim City Manager, or his designee, is hereby authorized to accept and execute a clinical study agreement with Merck and Company, Inc., in the amount of \$53,175.00 in order for the San Antonio Metropolitan Health District to participate in a clinical study to evaluate a vaccine against measles, mumps and rubella diseases in healthy children 12 to 18 months of age beginning on January 10, 2005 and continuing for approximately ten months. A copy of the agreement, in substantially correct form, is set out in Attachment II and incorporated herein for all purposes.

SECTION 2. SAP Fund No. 26012000, Funds Center 3607790000, Cost Center 3607790001, Internal Order 136000000252, is hereby designated for use in accounting for the fiscal transactions of the Merck Vaccine Study 010-00.

SECTION 3. The sum of \$53,175.00.00 is hereby appropriated in the above-designated fund, and the budget attached hereto and incorporated herein as Attachment I is approved and adopted for entry on the City books.

SECTION 4. Payments in an aggregate amount not to exceed \$2,500.00 are authorized to be paid out as stipends of up to \$50.00 to the family of each participant in the clinical study. Payment will be made from SAP Fund No. 26012000, Cost Center 3607790001, Internal Order 136000000252, SAP GL No. 5202025, Other Contractual Services.

SECTION 5. The two (2) personnel positions set out in Attachment I are hereby authorized for the Merck Vaccine Study 010-00.

SECTION 6. The Director of Finance may, subject to concurrence by the Interim City Manager or the Interim City Manager's designee, correct allocation to specific fund numbers, internal order numbers, and SAP GL account numbers and as necessary to carry out the purpose of this ordinance.

SECTION 7. Should the agreement awarded be in an amount other than that budgeted for, or should the agreement contain terms and conditions different than those currently existing, acceptance of the agreement, budget and corresponding personnel complement will be subject to subsequent City Council ordinance.

SECTION 8. This ordinance shall be effective on and after February 27, 2005.

PASSED AND APPROVED this 17th day of February, 2005.




M A Y O R

EDWARD D. GARZA

ATTEST:


City Clerk

APPROVED AS TO FORM:


City Attorney